Kwality Pharmaceuticals Ltd

Pursuant to Regulation 30 & 33 read with clause 4(h) of Para A Part A of Schedule III of SEBI(Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) this is to inform you that Board of Directors in its meeting held today i.e. 14th February 2023 have inter-alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December 2022 along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith.